FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2294162426> ?p ?o ?g. }

• W2294162426 abstract "Leiomyosarcoma (LMS) is a common type of soft tissue sarcoma that responds poorly to standard chemotherapy. Thus the goal of this study was to identify novel selective therapies that may be effective in leiomyosarcoma by screening cell lines with a small molecule library comprised of 480 kinase inhibitors to functionally determine which signalling pathways may be critical for LMS growth. LMS cell lines were screened with the OICR kinase library and a cell viability assay was used to identify potentially effective compounds. The top 10 % of hits underwent secondary validation to determine their EC50 and immunoblots were performed to confirm selective drug action. The efficacy of combination drug therapy with doxorubicin (Dox) in vitro was analyzed using the Calcusyn program after treatment with one of three dosing schedules: concurrent treatment, initial treatment with a selective compound followed by Dox, or initial treatment with Dox followed by the selective compound. Single and combination drug therapy were then validated in vivo using LMS xenografts. Compounds that targeted PI3K/AKT/mTOR pathways (52 %) were most effective. EC50s were determined to validate these initial hits, and of the 11 confirmed hits, 10 targeted PI3K and/or mTOR pathways with EC50 values <1 μM. We therefore examined if BEZ235 and BKM120, two selective compounds in these pathways, would inhibit leiomyosarcoma growth in vitro. Immunoblots confirmed on-target effects of these compounds in the PI3K and/or mTOR pathways. We next investigated if there was synergy with these agents and first line chemotherapy doxorubicin (Dox), which would allow for earlier introduction into patient care. Only combined treatment of BEZ235 and Dox was synergistic in vitro. To validate these findings in pre-clinical models, leiomyosarcoma xenografts were treated with single agent and combination therapy. BEZ235 treated xenografts (n = 8) demonstrated a decrease in tumor volume of 42 % whereas combining BEZ235 with Dox (n = 8) decreased tumor volume 68 % compared to vehicle alone. In summary, this study supports further investigation into the use of PI3K and mTOR inhibitors alone and in combination with standard treatment in leiomyosarcoma patients." @default.
• W2294162426 created "2016-06-24" @default.
• W2294162426 creator A5001815966 @default.
• W2294162426 creator A5002804852 @default.
• W2294162426 creator A5004411374 @default.
• W2294162426 creator A5007657275 @default.
• W2294162426 creator A5018005429 @default.
• W2294162426 creator A5029398617 @default.
• W2294162426 creator A5029799609 @default.
• W2294162426 creator A5035216749 @default.
• W2294162426 creator A5036624979 @default.
• W2294162426 creator A5053803373 @default.
• W2294162426 creator A5062768191 @default.
• W2294162426 creator A5067597035 @default.
• W2294162426 date "2016-03-08" @default.
• W2294162426 modified "2023-10-16" @default.
• W2294162426 title "PI3K/AKT/mTOR inhibition in combination with doxorubicin is an effective therapy for leiomyosarcoma" @default.
• W2294162426 cites W1513377274 @default.
• W2294162426 cites W185148555 @default.
• W2294162426 cites W1979782687 @default.
• W2294162426 cites W1981711832 @default.
• W2294162426 cites W1982933649 @default.
• W2294162426 cites W1986115996 @default.
• W2294162426 cites W1991628301 @default.
• W2294162426 cites W1991968471 @default.
• W2294162426 cites W1996608464 @default.
• W2294162426 cites W2000095508 @default.
• W2294162426 cites W2014620054 @default.
• W2294162426 cites W2018133454 @default.
• W2294162426 cites W2020953583 @default.
• W2294162426 cites W2030866834 @default.
• W2294162426 cites W2039628288 @default.
• W2294162426 cites W2043275588 @default.
• W2294162426 cites W2054993939 @default.
• W2294162426 cites W2057680622 @default.
• W2294162426 cites W2060695865 @default.
• W2294162426 cites W2065919583 @default.
• W2294162426 cites W2067743294 @default.
• W2294162426 cites W2086797990 @default.
• W2294162426 cites W2094277516 @default.
• W2294162426 cites W2094507483 @default.
• W2294162426 cites W2096439168 @default.
• W2294162426 cites W2103562758 @default.
• W2294162426 cites W2121425239 @default.
• W2294162426 cites W2125100184 @default.
• W2294162426 cites W2126782531 @default.
• W2294162426 cites W2139712038 @default.
• W2294162426 cites W2141884409 @default.
• W2294162426 cites W2143393758 @default.
• W2294162426 cites W2143882684 @default.
• W2294162426 cites W2148848488 @default.
• W2294162426 cites W2152127926 @default.
• W2294162426 cites W2154871907 @default.
• W2294162426 cites W2156768359 @default.
• W2294162426 cites W2157561781 @default.
• W2294162426 cites W2158305336 @default.
• W2294162426 cites W2159111655 @default.
• W2294162426 cites W2163239105 @default.
• W2294162426 cites W2165404212 @default.
• W2294162426 cites W2166453182 @default.
• W2294162426 cites W2168133196 @default.
• W2294162426 cites W2168270349 @default.
• W2294162426 cites W2388163742 @default.
• W2294162426 cites W4241146545 @default.
• W2294162426 doi "https://doi.org/10.1186/s12967-016-0814-z" @default.
• W2294162426 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4782390" @default.
• W2294162426 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26952093" @default.
• W2294162426 hasPublicationYear "2016" @default.
• W2294162426 type Work @default.
• W2294162426 sameAs 2294162426 @default.
• W2294162426 citedByCount "37" @default.
• W2294162426 countsByYear W22941624262016 @default.
• W2294162426 countsByYear W22941624262017 @default.
• W2294162426 countsByYear W22941624262018 @default.
• W2294162426 countsByYear W22941624262019 @default.
• W2294162426 countsByYear W22941624262020 @default.
• W2294162426 countsByYear W22941624262021 @default.
• W2294162426 countsByYear W22941624262022 @default.
• W2294162426 countsByYear W22941624262023 @default.
• W2294162426 crossrefType "journal-article" @default.
• W2294162426 hasAuthorship W2294162426A5001815966 @default.
• W2294162426 hasAuthorship W2294162426A5002804852 @default.
• W2294162426 hasAuthorship W2294162426A5004411374 @default.
• W2294162426 hasAuthorship W2294162426A5007657275 @default.
• W2294162426 hasAuthorship W2294162426A5018005429 @default.
• W2294162426 hasAuthorship W2294162426A5029398617 @default.
• W2294162426 hasAuthorship W2294162426A5029799609 @default.
• W2294162426 hasAuthorship W2294162426A5035216749 @default.
• W2294162426 hasAuthorship W2294162426A5036624979 @default.
• W2294162426 hasAuthorship W2294162426A5053803373 @default.
• W2294162426 hasAuthorship W2294162426A5062768191 @default.
• W2294162426 hasAuthorship W2294162426A5067597035 @default.
• W2294162426 hasBestOaLocation W22941624261 @default.
• W2294162426 hasConcept C126322002 @default.
• W2294162426 hasConcept C142724271 @default.
• W2294162426 hasConcept C150903083 @default.
• W2294162426 hasConcept C185592680 @default.
• W2294162426 hasConcept C207001950 @default.
• W2294162426 hasConcept C2776694085 @default.
• W2294162426 hasConcept C2777532014 @default.

• next